

Please type a plus sign (+) inside this box ☒ PTO/SB/USA (08-00)Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/965,796
		Filing Date	October 1, 2001
		First Named Inventor	David M. Goldenberg
		Group Art Unit	1842 1643
		Examiner Name	HARRIS, Alana M
Sheet 1 of 1	Attorney Docket Number	40923-0079 US3	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
anh	A10	Oliver W. Press; "Prospects for the Management of Non-Hodgkin's Lymphomas with Monoclonal Antibodies and Immunoconjugates"; The Cancer Journal from Scientific American, vol. 4, Supplement 2, Pgs. S19-S26, 1998.	
↓	A12	M. Ghetie et al., "Evaluation of Ricin A Chain-containing Immunotoxins Directed against CD19 and CD22 Antigens on Normal and Malignant Human B-Cells as Potential Reagents for in Vivo Therapy," Cancer Research, 1988, 48, 2610-2617	
↓	A17	J. Leonard et al., "Epratuzumab, A New Anti-CD22, Humanized, Monoclonal Antibody for the Therapy of Non-Hodgkin's Lymphoma (NHL): Phase I/II Trial Results," Blood, vol 94, no. 10 suppl. 1 part 1, 1999, Abstract #404	
↓	A19	W. M. J. Vuist et al., "Potentiation by Interleukin 2 of Burkitt's Lymphoma Therapy with Anti-Pan B (Anti-CD19) Monoclonal Antibodies in a Mouse Xenotransplantation Model," Cancer Research, July 15, 1989, 49, 3783-3788	

Examiner Signature	anh Harris	Date Considered	11/30/2005
--------------------	------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.